List view / Grid view
Karen Pinachyan, Head of Medical Affairs Europe at CSL Behring provides an overview of past and present gene therapy development, plus the progress of clinical trials and key challenges in the sector.
The ITAC trial will establish if adding hyperimmune intravenous immunoglobulin (hIVIG) to a remdesivir regimen can improve hospitalised COVID-19 patient outcomes.
29 June 2015 | By Victoria White
The Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation in the EU for CSL Behring's Respreeza...
